Press Release

NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank
Jul 27, 2018 07:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities.
More info..

NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3
Jun 22, 2018 09:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS).
More info..

NANOBIOTIX' Management Statement on Recent Share Price Variation Jun 06, 2018 22:00 JST NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. More info..

Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers
May 04, 2018 09:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action.
More info..

AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway
Apr 18, 2018 09:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018).
More info..

The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab
Apr 11, 2018 09:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product.
More info..

Nanobiotix 2017 Annual Results
Mar 30, 2018 22:10 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017.
More info..

Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting
Jan 22, 2018 15:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors.
More info..

Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers
Jan 11, 2018 15:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy.
More info..

Nanobiotix: 2017 review and 2018 expected milestones Dec 26, 2017 15:50 JST NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides a recap of its activities and achievements in 2017 and an overview of its anticipated 2018 milestones. More info..

FDA approves Nanobiotix's first Immuno-Oncology trial Dec 26, 2017 15:15 JST A Phase I/II Study of NBTXR3 Activated by Radiation Therapy (SABR) for Patients with Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma Cancer Treated with an Anti-PD1 Antibody (Nivolumab or Pembrolizumab) More info..

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting
Nov 13, 2017 15:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. These data were presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held from November 8 to 12, 2017 in National Harbor, Maryland, USA.
More info..

Nanobiotix provides update on the global development of its lead product NBTXR3
Nov 10, 2017 08:30 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today provides an update on the global development of its lead product, NBTXR3.
More info..

Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma
Oct 23, 2017 14:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma. The last patients are expected to start their treatment in two to three weeks.
More info..

Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.
Sep 29, 2017 08:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today its intention to start a new trial in the company's immuno-oncology (IO) program. The trial is aimed at expanding the potential of NBTXR3 to recurrent and metastatic disease.
More info..

Nanobiotix half year results for the six months ended 30 June 2017 Sep 01, 2017 01:30 JST NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended 30 June 2017. More info..

NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop
Jun 16, 2017 06:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today presented new translational data at the "Immunotherapy workshop - Incorporating Radiation Oncology into Immunotherapy" co-sponsored by the American Society of Radiation Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC), that takes place from June 15 to 16, 2017 in Bethesda, Maryland, USA.
More info..

NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting
Jun 06, 2017 00:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, presented the results of the Phase I/II head and neck cancer trial with its lead product candidate, NBTXR3, at the American Society of Clinical Oncology (ASCO), Chicago.
More info..

Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become a Backbone in Immuno-Oncology
May 18, 2017 14:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its first set of clinical data from its immuno-oncology (IO) program, showing the potential ability of NBTXR3 to transform "cold" tumors into "hot" tumors.
More info..

Nanobiotix: 2016 Annual Results Apr 29, 2017 01:00 JST NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2016. More info..

Nanobiotix Expands Its Clinical Development in Head and Neck Cancer and Immuno-Oncology Apr 04, 2017 14:50 JST NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the expansion and acceleration of its clinical development activities. More info..

NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma
Mar 24, 2017 07:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that the Independent Data Monitoring Committee (IDMC) has completed the interim evaluation of the Phase II/III trial results (Act.In.Sarc) of NBTXR3 in soft tissue sarcoma.
More info..

Nanobiotix to Present Preclinical Data on Nanoparticle Radioenhancer NBTXR3 at the AACR Annual Meeting 2017
Mar 07, 2017 15:50 JST

NANOBIOTIX today announced the presentation of NBTXR3 preclinical studies demonstrating 1) the antitumor efficacy of NBTXR3 in five different in vivo human cancer models and 2) the antitumor efficacy of NBTXR3 in combination with chemotherapy, in both in vitro and in vivo studies.
More info..

Nanobiotix Appoints Senior Executive from Pharmaceutical Industry, as Chief Operating Officer
Feb 07, 2017 16:30 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO).
More info..

NANOBIOTIX: 2016 Review and 2017 Anticipated Milestones Feb 01, 2017 08:00 JST NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides its activities and achievements during 2016 and an overview of anticipated 2017 milestones. More info..

Nanobiotix Reports Positive Phase I/II Preliminary Data on Feasibility and Safety of NBTXR3 in Liver Cancers Trial
Dec 15, 2016 08:00 JST

NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces a positive readout of initial data on the safety and feasibility from the first patients treated in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and metastatic tumors.
More info..

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3
Nov 29, 2016 08:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides an update on the global development of its lead product, NBTXR3, across all indications.
More info..

Nanobiotix Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as In Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting
Nov 14, 2016 15:20 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces preclinical data demonstrating that its leading radioenhancer nanoparticle, NBTXR3, actively stimulates the host immune system to attack tumor cells.
More info..

Nanobiotix' Partner PharmaEngine Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia
Nov 07, 2016 17:00 JST

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205) today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. The trial is evaluating the optimal dose, safety and preliminary efficacy of Nanobiotix's lead product.
More info..